EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
European Journal of Cancer2006Vol. 42(15), pp. 2433–2453
Citations Over TimeTop 1% of 2006 papers
Matti Aapro, David Cameron, Ruth Pettengell, Julia Bohlius, Jeffrey Crawford, Michael Ellis, Nora Kearney, Gary H. Lyman, Vivianne C. G. Tjan‐Heijnen, Jan Walewski, Damien C. Weber, C. Zielinski
Related Papers
- → Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)(2013)84 cited
- → Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia(2004)14 cited
- → Intermittent granulocyte colony‐stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia(2012)7 cited
- [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].(2013)
- → Prospective randomised comparison of granulocyte colony-stimulating factor (G-CSF) (filgrastim) secondary prophylaxis versus conservative management of chemotherapy-induced neutropenia to maintain dose intensity in chemotherapy for breast cancer(2012)